Paid-in Capital Increase & Max Shareholder Change
에이프릴바이오
397030
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2719
Risk-adjusted indicator based on 2719 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Shares Issued: 4,095,456 Shares
- • Previous Shares Outstanding: 23,413,826 Shares
- • Maximum Dilution: 14.88%
- • Purpose of Funds: Operating Funds
AI Analysis Summary
AprilBio Co.,Ltd. announced a third-party allocation paid-in capital increase, issuing 4,095,456 new common shares. This will result in a maximum dilution of 14.88% for existing shareholders. The funds raised are designated for operating expenses. Concurrently, IMM Asset Management Co., Ltd. is expected to become the largest shareholder, acquiring the new shares and the existing largest shareholder's shares. While dilution is a negative, the capital injection and new major shareholder could provide stability and strategic direction, leading to a neutral to slightly positive short-term outlook.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.